Balchem Corporation — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Unless noted otherwise, amounts below are in U.S. dollars; financial figures are rounded to millions. Balchem develops and sells specialty ingredients and products across human nutrition and health (HNH), animal nutrition and health (ANH), and specialty products, including performance gases and plant nutrition.
Financial performance
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Net sales | $922.4m | $942.4m | Down 2.1% |
| Gross margin | $302.1m (32.7%) | $280.5m (29.8%) | Up $21.6m; margin +2.9 percentage points |
| Operating earnings | $159.2m (17.3%) | $145.2m (15.4%) | Up 9.6% |
| Net earnings | $108.5m | $105.4m | Up 3.0% |
| Diluted EPS | $3.35 | $3.25 | Up 3.1% |
| Cash from operations | $183.8m | $138.5m | Up $45.2m |
| Capital expenditures | $37.3m | $49.1m | Down $11.8m |
Higher gross margin reflected lower cost of sales, including lower manufacturing input costs, despite lower revenue. Operating expenses rose 5.6%, including restructuring-related impairment and asset disposal charges of $7.8m and acquired-business costs, partly offset by favorable transaction-cost adjustments. Net earnings growth was constrained by net interest expense rising to $22.6m from $10.3m, reflecting acquisition-related borrowings and higher interest rates. The effective tax rate was 20.9%, compared with 21.2%.
Segments
| Segment | FY2023 sales | Change vs. FY2022 | FY2023 operating earnings | Change vs. FY2022 |
|---|---|---|---|---|
| Human Nutrition and Health | $550.8m | Up 4.5% | $102.4m | Up 24.7% |
| Animal Nutrition and Health | $238.3m | Down 9.1% | $27.6m | Down 23.5% |
| Specialty Products | $126.0m | Down 4.2% | $34.6m | Up 5.5% |
| Other and Unallocated | $7.4m | Down 65.6% | $(5.4)m | Loss narrowed |
HNH growth reflected acquisitions, higher minerals and nutrients sales, and currency effects, partly offset by lower food and beverage sales. ANH weakness reflected lower monogastric and ruminant sales; volume/mix and pricing both declined. Specialty Products’ lower sales reflected weaker plant nutrition and performance gases demand, partly offset by higher prices.
Fourth-quarter context: Q4 2023 sales were $228.7m versus $232.5m in Q4 2022; net earnings were $26.6m versus $21.4m, and diluted EPS was $0.82 versus $0.66.
Cash, debt and liquidity
- Cash and cash equivalents were $64.4m at year-end, versus $66.6m a year earlier. Working capital was $165.8m, down from $195.8m.
- Revolving debt was $309.6m, down from $440.6m. The $550m senior secured revolver matures July 2027; $240.4m was available at year-end. Its stated interest rate was 6.58%. The company was in compliance with its financial covenants.
- Operating cash flow was $183.8m. Investing cash outflow was $34.8m, including $37.9m of capital expenditures and intangible asset purchases; financing cash outflow was $153.3m, including $131.0m of net revolving-loan payments and $22.9m of dividends paid.
- Management expects operating cash flow to fund working capital and necessary investment. Capital expenditures are projected at $35m–$40m for 2024. The filing gives no earnings or revenue guidance.
Outlook, risks and notable items
- Management reported improved supply reliability in 2023, but cited geopolitical challenges affecting some supply lanes and mixed inflationary and deflationary input-cost trends. Raw-material availability and pricing, competition, customer demand, foreign exchange and global economic conditions remain risks.
- Ethylene oxide is important to medical-device sterilization. EPA review and proposed mitigation measures, state scrutiny of emissions, and customer downtime to install abatement equipment could affect customer operations and Balchem sales. The company expects continued registration, but outcomes and timing are uncertain. Propylene oxide use for nuts and spices remained permitted under the interim decision; related changes awaited EPA review.
- At the Verona, Missouri site, Balchem and Syntex are conducting an EPA-supervised investigation into potential 1,4-dioxane and chlorobenzene releases. The company also received a DOJ notice concerning alleged Risk Management Plan Rule violations following an EPA inspection; discussions were expected in 2024. Balchem recorded a loss contingency it considers immaterial and cites indemnification relating to the site’s legacy Superfund liabilities.
- Restructuring-related impairment and disposal charges were $7.8m. Favorable acquisition transaction-cost adjustments materially affected year-over-year expense comparisons; the filing identifies $11.3m of favorable adjustments associated with Bergstrom in 2023. Acquisition earn-out periods concluded, leaving $0.1m of contingent consideration at year-end.
- Goodwill was $778.9m, and the annual impairment test found no impairment. The auditor identified goodwill valuation as a critical audit matter because fair values depend on forecasts, discount rates and terminal-value assumptions. The financial statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting.
- Variable-rate borrowing creates interest risk: a 100-basis-point rate change applied to year-end borrowings would change annual interest expense and cash flow by approximately $3.1m.
Most important facts for investors to verify
- Whether ANH demand and segment earnings stabilize after FY2023 declines, and whether HNH growth continues excluding acquisition contributions.
- EPA decisions and customer responses concerning ethylene oxide emissions and sterilization capacity, including any resulting interruptions or added costs.
- Progress, potential remedies and financial exposure from the Verona environmental investigation and DOJ discussions.
- Debt reduction, interest costs and covenant headroom under the floating-rate revolver, especially if rates or operating performance change.
- Assumptions supporting the valuation of the $778.9m goodwill balance and whether any future market or regulatory changes trigger impairment testing.